Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence

Semaglutide use shows association with increased NAION risk, particularly with prolonged exposure and in patients with predisposing factors. Risk-benefit assessment and targeted ophthalmologic monitoring are recommended while maintaining appropriate therapeutic use.